Getting Better at Diagnosing and Treating Postpartum Depression (PPD)
April 21, 2023
April 21, 2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with Depression and Bipolar Support Alliance (DBSA), The Policy Center for Maternal Mental Health, and American College of Osteopathic Obstetricians and Gynecologists (ACOOG)
This activity is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
The educational design of this activity addresses the needs of OB-GYNs, maternal-fetal medicine specialists, psychiatrists, psychologists, primary care physicians, NPs, PAs, and mental-health specialists, and other clinicians involved in the management of patients with postpartum depression (PPD).
Postpartum depression (PPD) remains an under-screened and underdiagnosed condition that affects maternal and infant health, as well as the well-being and safety of the entire family. Clinicians should be aware of the social, environmental, and neurochemical factors that contribute to the development of PPD in order to reduce the time to screening, diagnosis, and treatment.
Join an expert OB-GYN and a psychiatrist for an in-depth discussion of the factors associated with increased risk for PPD, as well as those that lead to inequalities in screening and diagnosis. Strategies to improve screening and diagnosis of PPD, especially in high-risk groups, will be shared. Panelists will also explore the evolving therapeutic landscape for PPD, which has expanded beyond selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) to include fast-acting and long-lasting neuroactive steroids.
Do you have patients at risk for or diagnosed with PPD who could benefit from education on symptoms, screening, and current and emerging treatment options? Direct your patients to MedLive.com to access the activity, “Is this Postpartum Depression (PPD)? Faster Recognition and Treatment of PPD.”
After completing this activity, the participant should be better able to
- Review factors associated with higher risk of PPD in women
- Discuss strategies to navigate barriers to screening and diagnosis of PPD
- Describe the limitations of traditional antidepressants in the treatment of PPD
- Evaluate clinical data related to emerging neuroactive steroid agents for the treatment of PPD
Shania J. Seibles, DO, JD
Maternal Fetal Medicine Physician
Kristina Deligiannidis, MD
Director, Women’s Behavioral Health
Zucker Hillside Hospital
Professor of Psychiatry
Molecular Medicine and Obstetrics & Gynecology
Donald and Barbara Zucker School or Medicine at Hofstra/Northwell
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Shania J. Seibles, DO, JD, has no relevant financial relationships to disclose.
- Kristina Deligiannidis, MD
- Consultant, Advisor, Speaker: Brii Biosciences, Gerbera Therapeutics, GH Research, Neuroscience Software, Reunion Neuroscience, Sage Therapeutics, Inc.
- Researcher: National Institutes of Health, Premier Healthcare, Sage Therapeutics, Inc., Woebot Health
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
There is no fee for this educational activity.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this activity, please visit https://partnersed.com.
For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”